Correlation Between Kodiak Sciences and Reviva Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Kodiak Sciences and Reviva Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kodiak Sciences and Reviva Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Kodiak Sciences and Reviva Pharmaceuticals Holdings, you can compare the effects of market volatilities on Kodiak Sciences and Reviva Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kodiak Sciences with a short position of Reviva Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kodiak Sciences and Reviva Pharmaceuticals.

Diversification Opportunities for Kodiak Sciences and Reviva Pharmaceuticals

0.38
  Correlation Coefficient

Weak diversification

The 3 months correlation between Kodiak and Reviva is 0.38. Overlapping area represents the amount of risk that can be diversified away by holding Kodiak Sciences and Reviva Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Reviva Pharmaceuticals and Kodiak Sciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kodiak Sciences are associated (or correlated) with Reviva Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Reviva Pharmaceuticals has no effect on the direction of Kodiak Sciences i.e., Kodiak Sciences and Reviva Pharmaceuticals go up and down completely randomly.

Pair Corralation between Kodiak Sciences and Reviva Pharmaceuticals

Considering the 90-day investment horizon Kodiak Sciences is expected to under-perform the Reviva Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Kodiak Sciences is 1.33 times less risky than Reviva Pharmaceuticals. The stock trades about -0.07 of its potential returns per unit of risk. The Reviva Pharmaceuticals Holdings is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  124.00  in Reviva Pharmaceuticals Holdings on November 28, 2024 and sell it today you would earn a total of  17.00  from holding Reviva Pharmaceuticals Holdings or generate 13.71% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Kodiak Sciences  vs.  Reviva Pharmaceuticals Holding

 Performance 
       Timeline  
Kodiak Sciences 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Kodiak Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in March 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Reviva Pharmaceuticals 

Risk-Adjusted Performance

Modest

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Reviva Pharmaceuticals Holdings are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Reviva Pharmaceuticals demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Kodiak Sciences and Reviva Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Kodiak Sciences and Reviva Pharmaceuticals

The main advantage of trading using opposite Kodiak Sciences and Reviva Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kodiak Sciences position performs unexpectedly, Reviva Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reviva Pharmaceuticals will offset losses from the drop in Reviva Pharmaceuticals' long position.
The idea behind Kodiak Sciences and Reviva Pharmaceuticals Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Complementary Tools

Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings